Dr. Reddys Laboratories Ltd.

Dr. Reddy’s Laboratories has completed the purchase of worldwide exclusive intellectual property rights for Fondaparinux sodium, its generic anti-coagulant drug from its Australian partner, Alchemia. The company had earlier signed a term sheet for this transaction in September, 2015.

Alchemia’s shareholders approved the sale of Fondaparinux at the company’s annual general meeting held on November 10, 2015 pursuant to which Dr. Reddy’s and Alchemia have executed a purchase and sale agreement, together with various patent assignment deeds. Alchemia has received $17.5 million from Dr. Reddy’s as consideration for the sale. The agreement is effective from July, 2015.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.